<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03914443</url>
  </required_header>
  <id_info>
    <org_study_id>JCOG1804E</org_study_id>
    <nct_id>NCT03914443</nct_id>
  </id_info>
  <brief_title>A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma</brief_title>
  <official_title>A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma FRONTiER Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Japan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fiverings Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Center, Japan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety of the neoadjuvant therapy,
      nivolumab with CF (5-FU, CDDP) or nivolumab with DCF (5-FU, CDDP, DTX), for locally advanced
      esophageal carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2019</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of participants with dose limiting toxicities (DLTs)</measure>
    <time_frame>from initial dose to 30 post-operative days</time_frame>
    <description>To evaluate the safety of combination chemotherapy with nivolumab as neoadjuvant Tx</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate (RR): percentage of participants with with a best response of CR or PR</measure>
    <time_frame>from baseline to date of disease progression, approximately 24 months</time_frame>
    <description>To evaluate the efficacy of combination chemotherapy with nivolumab as neoadjuvant Tx</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological complete response rate</measure>
    <time_frame>from baseline to operation, average of 10 weeks after initial dose</time_frame>
    <description>To evaluate the efficacy of combination chemotherapy with nivolumab as neoadjuvant Tx</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radical resection rate</measure>
    <time_frame>at operation, average of 10 weeks after initial dose</time_frame>
    <description>To evaluate the efficacy of combination chemotherapy with nivolumab as neoadjuvant Tx</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment completion rate</measure>
    <time_frame>from baseline to operation, average of 10 weeks after initial dose</time_frame>
    <description>To evaluate the efficacy of combination chemotherapy with nivolumab as neoadjuvant Tx</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event (AE) expression rate</measure>
    <time_frame>up to 30 postoperative days</time_frame>
    <description>To evaluate the safety of combination chemotherapy with nivolumab as neoadjuvant Tx</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>from baseline to date of disease progression or death, approximately 24 month</time_frame>
    <description>To evaluate the efficacy of combination chemotherapy with nivolumab as neoadjuvant Tx</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>from baseline to date of death, approximately 24 month</time_frame>
    <description>To evaluate the efficacy of combination chemotherapy with nivolumab as neoadjuvant Tx</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Locally Advanced Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>&quot;Nivolumab: 360 mg, every 3 week 5-FU: 800 mg/m^2, every 3 week CDDP: 80 mg/m^2, every 3 week &quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>&quot;Nivolumab: 240 mg lead-in followed by 360 mg, every 3 week 5-FU: 800 mg/m^2, every 3 week CDDP: 80 mg/m^2, every 3 week &quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>&quot;Nivolumab: 360 mg, every 3 week 5-FU: 750 mg/m^2, every 3 week CDDP: 70 mg/m^2, every 3 week DTX: 70mg/m^2, every 3 weeks&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>&quot;Nivolumab: 240 mg lead-in followed by 360 mg, every 3 week 5-FU: 750 mg/m^2, every 3 week CDDP: 70 mg/m^2, every 3 week DTX: 70mg/m^2, every 3 weeks&quot;</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>240 mg or 360 mg</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_label>Cohort D</arm_group_label>
    <other_name>ONO-4538</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>750 or 800 mg^2</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_label>Cohort D</arm_group_label>
    <other_name>5-Fluorouracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CDDP</intervention_name>
    <description>70 or 80 mg/m^2</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_label>Cohort D</arm_group_label>
    <other_name>Cisplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DTX</intervention_name>
    <description>70 mg/m^2</description>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_label>Cohort D</arm_group_label>
    <other_name>Docetaxel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Endoscopic biopsy of esophageal primary lesion histologically diagnosed as squamous
             cell carcinoma, adenosquamous carcinoma or basal cell carcinoma

          2. All esophageal cancer lesions are localized in the thoracic esophagus

          3. Patients are classified as clinical stage T1N1-3M0 or T2-3N0-3M0 in the UICC-TNM
             classification 8th edition

          4. The age is over 20 years old and under 75 on the enrollment date

          5. PS 0-1

          6. With or without measurable lesions

          7. Patients who have no medical history of treatment for esophageal cancer

          8. Patients who have no medical history of chemotherapy, radiotherapy and endocrine
             therapy including treatment for other types of cancer

          9. The results of laboratory tests within 14 days before enrollment meet the inclusion
             criteria

         10. Esophageal cancer radical surgery (R0) by open-chest surgery (or thoracoscopic
             surgery) and laparotomy (or laparoscopic surgery) is judged possible

         11. Patients who have no complication or history of thyroid dysfunction

         12. Patients who have no complication or history of autoimmune disease

         13. Patients who don't have treatment with systemic corticostroids (dose of 10mg/day over
             in prednisolone equivalent) or imunosuppressants within 14 days before enrollment

         14. Patinets who have no complication or hisoty of pneumonitis or pulmonary fibrosis which
             had been diagnosed by imaging tests or phisical examination

         15. For females, who have agreed with contraception from start of investigational drug
             administration to 5 months after last dose of investigational drug. For males who have
             agreed with contraception from start of investigational drug administration to 7
             months after last dose of investigational drug.

         16. Obtained the written informed consent from patients&quot;

        Exclusion criteria:

          1. Patients who have active multiple cancers

          2. Patients who have infectious disease which is active and need the systemic treatment

          3. Positive with HBs antigen, or HCV-RNA or anti HIV antibody, or anti HTLV-1 antibody
             tests

          4. Negative with HBs antigen test and positive with anti HBs antibody or anti HBc
             antibody tests, and positive with HBV-DNA quantitative test

          5. Pregnant, suspected pregnant or lactating

          6. Patients who have Psycosis or psychiatric symptoms are judged inappropriate for
             paticipation of the trial

          7. Patients who need the treatment with continued use of flucytosine, phenytoin or
             warfalin pottasium

          8. Ptients who have a medical history of allergy to iodine

          9. Patients who have hypersensitivity to docetaxel, cisplatin, and drug containing
             polysorbate 80

         10. Patients who have a complication or a history of highly sensitive reactions to
             antibody formulations

         11. Even if insulin or oral hypoglycemic agent is continued to use, the result of HbA1c
             test is 6.5% or more in JDS or 6.9% or more in NGSP

         12. Patients who have advanced pulmonary emphysema which is observed by pulmonary function
             test or CT test

         13. Patients who have uncontrollable hypertension

         14. Patients who have unstable angina or a medical history of myocardial infarction within
             6 months before for enrollment

         15. Patients who have diverticulitis or symptomatic peptic ulcer disease

         16. Patients who have history of transplantation therapy such as hematopoietic stem cell
             transplantation

         17. Patients who have medical history of treatment with anti PD-1 antibody, anti PD-L1
             antibody, anti PD-L2 antibody, anti CD137 antibody, anti CTLA-4 antibody or any other
             antibody for inhibition or modulation of T cell costimulatory pathway or cancer
             vaccine&quot;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ken Kato, MD/PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Gastrointestinal Medical Oncology, National cancer center hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tatsushi Goto</last_name>
    <phone>+81-6-6358-7004</phone>
    <email>gotou@fiverings.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ken Kato, M.D./Ph.D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>April 11, 2019</study_first_submitted>
  <study_first_submitted_qc>April 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2019</study_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Esophageal squamous cell carcinoma</keyword>
  <keyword>Neoadjuvant chemotherapy</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>JCOG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

